Stimulation of an immune response by cationic lipids
AssigneePDS Biotechnology Corporation
InventorsWeihsu Chen, Weili Yan, Kenya Toney, Gregory Conn, Frank Bedu-Addo, Leaf Huang
Life of this patent
Estimating the term…
Abstract
The present invention provides compositions and methods for stimulating an immune response using cationic lipids alone or in combination with antigens.
Claims44
A method of treating a disease or infection in a mammal, the method comprising administering at least one cationic lipid together with at least one tumor-associated antigen or naturally-occurring microbial antigen, wherein the cationic lipid is administered to the mammal in an amount sufficient to activate the MAP kinase signaling pathway to elicit an immunostimulatory adjuvant effect,
- wherein a mouse dose of cationic lipid is between 10 nmol and about 400 nmol,
- and wherein the mammal dose of cationic lipid is determined from the mouse dose.
A method of reducing the regulatory T-cell population in a mammal in need thereof, the method comprising administering to the mammal at least one cationic lipid and at least one tumor-associated antigen or naturally-occurring microbial antigen,
- wherein a mouse dose of cationic lipid is between 10 nmol and about 400 nmol,
- and wherein the mammal dose of cationic lipid is determined from the mouse dose.
A method of using a cationic lipid to elicit an immunostimulatory adjuvant effect in an immune system of a mammal, wherein the cationic lipid is administered with at least one tumor-associated antigen or naturally-occurring microbial antigen to the mammal in an amount sufficient to activate the MAP kinase signaling pathway to elicit the immunostimulatory adjuvant effect,
- wherein a mouse dose of cationic lipid is between 10 nmol and about 400 nmol,
- and wherein the mammal dose of cationic lipid is determined from the mouse dose.
A method of inducing an antibody response against an antigen in a mammal, the method comprising administering at least one cationic lipid together with at least one tumor-associated antigen or naturally-occurring microbial antigen, wherein the cationic lipid is administered to the mammal in an amount sufficient to induce the antibody response in response against the antigen,
- wherein a mouse dose of cationic lipid is between 10 nmol and about 400 nmol,
- and wherein the mammal dose of cationic lipid is determined from the mouse dose.
Dependencies are inferred from the claim text.